The specificity of these molecules is a premise for the treatment of MFN2-associated disorders (e.g., inherited peripheral neuropathy Charcot–Marie–Tooth disease type 2A (CMT2A) [89]) and for the possibility to control the different cell pathways in which MFN2 is involved. This evidence concerns the gene MFN2 and Charcot-Marie-Tooth disease type 2A1.